55-85-6

Basic information

• Product Name: DIMETHYLAMINO-ACETIC ACID HYDRAZIDE
• Synonyms: DIMETHYLAMINO-ACETIC ACID HYDRAZIDE;GIRARD'S ''D'' REAGENT;Glycine, N,N-diMethyl-, hydrazide
• CAS NO: 55-85-6
• Molecular Formula: C₄H₁₁N₃O
• Molecular Weight: 117.15
• Mol File: 55-85-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 256.1 °C at 760 mmHg
• Flash Point: 108.7 °C
• Appearance: /
• Density: 1.051 g/cm³
• CAS DataBase Reference: DIMETHYLAMINO-ACETIC ACID HYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: DIMETHYLAMINO-ACETIC ACID HYDRAZIDE(55-85-6)
• EPA Substance Registry System: DIMETHYLAMINO-ACETIC ACID HYDRAZIDE(55-85-6)

Safety Data

• Hazardous Substances Data: 55-85-6(Hazardous Substances Data)

Usage

General Description

Dimethylamino-acetic acid hydrazide, also known as DMAAH, is a chemical compound with the molecular formula C4H12N4O2. It is an organic hydrazide that is commonly used as a reagent for the preparation of heterocycles and pharmaceutical intermediates. DMAAH has also been studied for its potential use in the treatment of neurodegenerative diseases due to its ability to inhibit the aggregation of amyloid proteins, which are implicated in conditions such as Alzheimer's disease. Additionally, it has been explored for its role in the synthesis of novel antitumor compounds. DMAAH is a versatile compound with various potential applications in both the pharmaceutical and research fields.

Upstream product

• 33229-89-9 N,N-dimethylglycine ethyl ester 
• 2491-06-7 N,N-dimethylglycine hydrochoride 

Downstream Products

• 92027-38-8 4-Phenyl-1-dimethylaminoacetyl-semicarbazid 
• 102410-32-2 Dimethylamino-acetic acid [1-(6-phenyl-imidazo[2,1-b]thiazol-5-yl)-meth-(E)-ylidene]-hydrazide 
• 84967-12-4 (Acetyl-hydrazono)-(2-ethoxycarbonylamino-phenyl)-acetic acid 
• 72606-25-8 C₁₄H₂₁N₃O 
• 72606-34-9 C₁₅H₂₃N₃O 
• 33083-43-1 5-dimethylaminomethyl-3H-[1,3,4]oxadiazol-2-thione 
• 1009621-56-0 cyclohexyl-hydroxy-phenyl-acetic acid N'-(2-dimethylaminoacetyl)-hydrazide 
• 1452467-58-1 (2R,5S)-6-(benzyloxy)-N’-[(dimethylamino)acetyl]-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide 
• 1049636-95-4 dimethylamino-acetic acid N'-((R)-2-cyclohexyl-2-hydroxy-2-phenyl-acetyl)-hydrazide 
• 395104-99-1 {5-[3-(4-Fluoro-phenyl)-1H-indazol-5-yl]-4H-[1,2,4]triazol-3-ylmethyl}-dimethyl-amine 

Relevant articles and documents

SUBSTITUTED INDAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are methods for treating and preventing malaria and/or Babesiosis, the methods comprising administering an effective amount of Indazole Compounds having the formulas: (I)[Formula (I) should be inserted here] or (II)[Formula (II) should be inserted here] wherein R1, R2, R3 and Y are as defined herein.

Indazole compounds, compositions thereof and methods of treatment therewith

This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.

Indazole derivatives as JNK inhibitors and compositions and methods related thereto

Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.